New drug shows promise for Hard-to-Treat lung cancer

NCT ID NCT03260491

Ongoing Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a drug called HER3-DXd in people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The study includes patients with specific genetic changes (EGFR or KRAS mutations) whose cancer worsened after other treatments. The goal is to check safety and see if the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HER3-DXd (patritumab deruxtecan)
What this could lead to: If successful, this could provide a new treatment option for patients with advanced lung cancer who have not responded to other therapies.
What could go wrong: This is an early-phase trial, so the drug may not prove effective or may cause unexpected side effects. Results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma neoplasm Neoplasm Metastasis non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Chung Shan Medical University Hospital

Taichung, 40705, Taiwan
City of Hope

Duarte, California, 91010, United States
Clinica Universidad Navarra(Madrid)

Madrid, 28027, Spain
Clínica Universidad de Navarra (Pamplona)

Pamplona, 31008, Spain
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Gabrail Cancer Center (GCC) - Canton Facility

Canton, Ohio, 44718-2566, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Hospital General Universitario Gregorio Maranon (HGUGM)

Madrid, 28007, Spain
Hospital Ramón y Cajal

Madrid, 28034, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC)

Madrid, 28050, Spain
Hospital Universitario Quirónsalud Madrid

Madrid, 28223, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Kindai University Hospital

Osaka, 5898511, Japan
Kurume University - Kurume University Hospital - Respiratory Diseases Center

Kurume-Shi, 830-0011, Japan
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
NEXT Oncology - Hospital Quironsalud Barcelona

Barcelona, 08023, Spain
NYU Langone Health - NYU Medical Oncology Associates

New York, New York, 10016-4744, United States
National Cancer Center Hospital East (NCCHE) - Kashiwa Campus

Kashiwa-Shi, 277-8577, Japan
National Cheng Kung University Hospital

Tainan, 00704, Taiwan
National Taiwan University Hospital

Taipei, 00100, Taiwan
Netherlands Cancer Institute

Amsterdam, 1066 CX, Netherlands
Northwest Medical Specialties

Tacoma, Washington, 98405, United States
Oncology Consultants P.A.

Houston, Texas, 77030, United States
Pacific Shores Medical Group

Long Beach, California, 90813, United States
Samsung Medical Center

Seoul, 06351, South Korea
Sarah Cannon Research Institute/Tennesse Oncology

Nashville, Tennessee, 37203, United States
Seoul National University Hospital

Seoul, 03080, South Korea
Shizuoka Cancer Center

Shizuoka, 4118777, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR)

Tokyo, 1358550, Japan
University of California San Diego

La Jolla, California, 92093, United States
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232-1301, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.